Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 17/20 | 0.46 |
| ▸ | BRAF | P15056 | 17/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3864318 | 0.93 | NOTUM (0.49) | FLT1KDRKITBRAFNOTUM | |
| SCHEMBL3873870 | 0.90 | KIT (0.49) | FLT1KDRKITBRAF | |
| SCHEMBL3866845 | 0.90 | FLT1 (0.50) | FLT1KDRKITBRAFNOTUM | |
| SCHEMBL3868940 | 0.89 | FLT1 (0.45) | FLT1KDRKITBRAF | |
| SCHEMBL3868124 | 0.89 | KIT (0.47) | FLT1KDRKITBRAF | |
| SCHEMBL3874914 | 0.87 | FLT1 (0.48) | FLT1KDRKITBRAF | |
| SCHEMBL3870092 | 0.85 | FLT1 (0.48) | FLT1KDRKITBRAF | |
| SCHEMBL3871163 | 0.83 | KIT (0.49) | FLT1KDRKITBRAF | |
| SCHEMBL3865214 | 0.83 | KIT (0.43) | FLT1KDRKITBRAF | |
| SCHEMBL3875124 | 0.82 | KIT (0.47) | FLT1KDRKITBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615565-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-10 | — | — | US | disclosed |
| US-7517894-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER SCHERING PHARMA AG (DE) | 2009-04-14 | — | — | US | disclosed |
| US-20070015794-A1 | Endothelial growth factor; angiogenesis inhibitors; antitumor agents; skin disorders; endimetriosis; Crohn's disease; leukemia; antiarthritic agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
| US-7148357-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | SCHERING AG (DE) | 2006-12-12 | — | — | US | disclosed |
| CN-1671666-A | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridine compounds | SCHERING AG (DE) | 2005-09-21 | — | — | CN | disclosed |
| US-20050054654-A1 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2005-03-10 | — | — | US | disclosed |
| US-20040147535-A1 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015794-A1 | Endothelial growth factor; angiogenesis inhibitors; antitumor agents; skin disorders; endimetriosis; Crohn's disease; leukemia; antiarthritic agents | FLT4, KDR, FLT1 | FLT1 3/4885KDR 2/4885KIT 80/4885 |
| US-20040147535-A1 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | FLT4, KDR, FLT1 | FLT1 3/4885KDR 2/4885KIT 28/4885 |
| US-20050054654-A1 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | FLT4, KDR, FLT1 | FLT1 3/4885KDR 2/4885KIT 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.